12:00 AM
 | 
Oct 29, 2007
 |  BC Week In Review  |  Company News  |  Deals

Bioenvision, Genzyme deal

BIVN's stockholders voted to approve the acquisition of the company by GENZ for $5.60 per share, or about $345 million in cash. The...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >